FDA approves Eli Lilly’s Trulicity for type 2 diabetic patients

Last Updated on October 17, 2024 by The Health Master

USFDA approves Eli Lilly’s Trulicity to reduce cardiovascular risks in type 2 diabetic patients

(Reuters) – Eli Lilly and Co said on the U.S. Food and Drug Administration (USFDA) has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients.

The approval makes Trulicity the first and only type 2 diabetes drug approved to reduce heart related risks in adults with and without established cardiovascular disease, the company said in a statement.

Also read: Zydus gets USFDA approval for generic Canasa

• IP 2026 released: Salient Features
  January 7, 2026
• Drug alert: 205 drug samples declared as NSQ in November 2025
  December 25, 2025
• FDA Haryana is Redefining Drug Safety and MSMEs Growth
  December 17, 2025
• 10th edition of IP for standards of drugs in India
  December 9, 2025
• QR Code mandatory at every Medical Store for ADR reporting
  November 26, 2025
• Landmark Seminar by FDA Haryana on Spurious drugs and NDPS Misuse
  November 25, 2025